Phase 4 N=20 Study of Restylane and Perlane in the Correction of Peri-Oral Wrinkles
Peri-oral Wrinkles
Primary: Local and Systemic Adverse Events — 100 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Perioral Rejuvenation and Upper Lip Enhancement
Perioral Rejuvenation · Upper Lip Projection
Primary: Nasal Tip Projection — 0.601 ratio
N/A N=49 Prospective Pellevé™ Neck Wrinkle Study
Facial and Neck Rhytides
Primary: Change in Neck and Facial Wrinkles Using the Fitzpatrick Wrinkle Assessment — 74 percentage of participants
N/A N=60 Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose
Nasolabial Folds
Primary: Treatment Difference in VAS (Perlane Side - Perlane-L Side) With Difference in VAS >= 10 mm — 95 Participants
N/A N=25 Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles
Rhytides · Wrinkle
Primary: Subject Satisfaction — 2.8 score on a scale
Phase 3 N=26 Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A
Wrinkles
Primary: Posttreament Results of Chemical Peel if Botox A is Added as Pre-treatment — 1; 2 Units on a wrinkle severity scale — p=.002
N/A N=51 Clinical Study Evaluating the Safety and Effectiveness of The Tixel Fractional System in The Treatment of Periorbital Wrinkles
Wrinkle · Periorbital · Tixel 2
Primary: Percentage of Participants With Safety Adverse Events — 3.92 Percentage of Participants
Phase 4 N=30 Emervel for the Correction of Lower Face Wrinkles & Folds
Nasolabial Folds · Marionette Lines · Wrinkles
Primary: Number of Subjects With Naturalness of Expression in Motion (2D Video) — 30 Participants
N/A N=20 Assess the Impact of Lip Rejuvenation on Projected First Impressions and Mood Perceptions
Lip Rejuvenation
Primary: First Impressions — 46.756; 27.769; 46.391; 34.404 score on a scale
N/A N=202 RHA Redensity - Perioral Rhytids
Perioral Rhytids · Aging · Wrinkle
Primary: Change From Baseline in Perioral Rhytids Severity Rating Scale (PR-SRS) Score Rated by the Blinded Live Evaluator (BLE) at Week 8 After Last Treatment. — 121; 4; 29; 47…
Phase 3 N=42 Cryo-Touch II for the Treatment of Wrinkles
Facial Wrinkles
Primary: Number of Participants With Effectiveness and Safety Success — 30; 41 participants
N/A N=24 Confirmatory Study: Assessing the Efficacy and Safety of the AcusMu Microneedle Patch in Treating Periorbital Wrinkles
Wrinkle
Primary: Proportion of Participants With Improvement in Periorbital Wrinkles From Baseline — 10; 2; 8; 2 Participants
N/A N=40 Safety and Efficacy of Single Therapy Versus Double and Triple Therapy of the Pellevé™ Wrinkle Treatment System for the Treatment of Moderate Facial Wrinkles
Appearance of Facial Wrinkles
Primary: Fitzpatrick Wrinkle Assessment — 1.0; 1.5; 1.1 units on a scale, change in Fitzpatrick
N/A N=169 Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
Midface Volume Deficit
Primary: Percent Responders With 1 Point Improvement on the Medicis Midface Volume Scale — 67; 8 Participants
Phase 4 N=101 Prospective Evaluation of Facial Cosmetic Procedures
Cosmetic Techniques
Primary: Patient Satisfaction With Validated FACE-Q Aesthetics Survey — 28.0; 24.0; 36.0; 36.0 score on a scale
N/A N=68 Reducing Wrinkles Around the Eyes Using the Ulthera® System
Periorbital Wrinkles
Primary: Overall Improvement in Periorbital Wrinkles and Rhytids Around the Eyes — 47; 50 percentage of participants improved
Phase 3 N=121 Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
Skin Aging
Primary: Treatment Success — 89.08 % of participants
N/A N=15 Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles
Rhytides · Wrinkle
Primary: Change in Facial Wrinkles at 12 Weeks Post Final Treatment Compared to Baseline — -0.10 units on a scale
N/A N=138 JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines
Patients With Moderate to Severe Perioral Lines
Primary: Percentage of Participants With at Least a 1 Point Improvement From Baseline on the Perioral Lines Severity Scale (POLSS) — 87; 72 percentage of participants
N/A N=100 Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate and Severe Nasolabial Folds
Nasolabial Folds in Chinese Population
Primary: Mean Change From Baseline in Wrinkle Severity Rating Scale (WSRS) at 6 Months — -0.03; 0.03 units on a scale
N/A N=51 TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides
Wrinkles · Rhytides
Primary: Changes to the Surface by Visual and Photographic Analysis. — 41 participants
N/A N=30 An Open-label Study of Poly-l-lactic Acid for Correction of Wrinkles in the décolletage Area
Wrinkles in Decolletage
Primary: Percentage of Responders on the Galderma Décolletage Scale (GDS), as Assessed Live by the Treating Investigator, at Month 9 — 93.8; 78.6 percentage of Participants
N/A N=25 TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides
Wrinkles · Rhytides
Primary: Fitzpatrick Classification of Wrinkling and Degree of Elastosis. — 5.6; 5.56; 5.36; 5.32 Fitzpatrick Classification Scale
N/A N=60 Safety & Tolerability Study That Compares Restylane to Restylane With Lidocaine While Correcting Wrinkles in the Nasolabial Folds
Nasolabial Folds
Primary: Treatment Difference in Pain as Measured by a Visual Analogue Scale — 44.9; 14.7 Scores on a VAS Scale
N/A N=99 A Study of Octave System for Improving Lines and Wrinkles of the Décolleté
Décolleté Wrinkles
Primary: Percentage of Treated Subjects With Improvement in Lines and Wrinkles of the Décolleté at Day 90 — 62.2 percentage of subjects
Phase 2 N=15 Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds
Nasolabial Folds
Primary: Difference in Wrinkle Assessment Score, Between Pre-treatment and 12 Weeks Post-treatment. — 1.13 units on a scale
N/A N=148 Restylane Defyne for Correction of Chin Retrusion
Chin Retrusion
Primary: Percentage of Participants (Responders) With At Least 1-Point Improvement From Baseline on the GCRS, as Assessed by the Blinded Evaluator at Month 6 ([Baseline…
Phase 3 N=917 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile — 21.3; 20.6; 0.0 Percentage of participants
N/A N=30 RHA® Redensity With New Anesthetic Agent - Perioral Rhytids
Aging · Pain
Primary: Non-inferiority of RHA® Redensity With New Anesthetic Agent Versus RHA® Redensity With Lidocaine in Terms of Reducing Pain During Device Injection Into the Upper…
Phase 3 N=118 Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®.
Facial Wrinkles
Primary: Adjusted (LS) Mean Change From Baseline in Wrinkle Severity Rating Scale (SRS) Score of Each Nasolabial Fold (NLF) as Determined by the Blinded Evaluator at Week 12…